Christian Vincent began his career as a researcher in biochemistry at the French National Research Centre (CNRS)
for nearly 10 years. From 1985 to 1990, he joined the international publishing group ELSEVIER as the scientific director
of BIOFUTUR, a monthly biotechnology magazine.

He joined the management of the Life Sciences Division of the French Atomic Energy Commission (CEA)
at the end of the year 1990 (1500 researchers). It creates and manages the Technical Transfer Office.
Two main missions: industrial property and industrial partnerships. Some key facts: a portfolio of 160 patent families,
68 million € of financial returns from this portfolio over the last 13 years, 20 to 30 new R&D and licensing contracts signed per year, creation of 24 start-up …

As part of his duties, he was for seven years a member of board of directors of CEA Investissement,
a subsidiary of CEA involved, in the creation of start-ups. He ran also SPI-BIO as its President from 1997 to 2004.
Founded in 1991 as a CEA Industries (named today AREVA) subsidiary,
this specialized company in drug development was sold to the BERTIN Group.

Since August 2013, he is an independent consultant in the fields of healthcare and biotechnology
and works closely with Neostrata Consulting for consulting assignments.
Along with this consultancy business, he is a member of the board of directors of the Société de Chimie Thérapeutique (SCT),
a learned society specialized in medicinal chemistry.



PhD in Biochemistry
Training modules for management of business units (HEC)


Comments are closed.